Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine + Oliceridine PCIA for Postoperative Pain in Nicotine Dependent Patients
NCT07306702Phase 4Withdrawn
- Sponsor
- Shenyang Sixth People's Hospital
- Start
- Jun 2026
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of dexmedetomidine in postoperative pain (3 arms), sponsored by Shenyang Sixth People's Hospital. Primary endpoint: Movement-evoked pain intensity at 48 hours. Planned start Jun 2026; status: withdrawn.
02
Drugs
dexmedetomidine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT07306702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07306702.